ESR1 and breast cancer: Genomic risk scores are also being used to assess whether omitting RNI is safe in patients with clinically node-positive BC or T3N0 BC who are ER+ and Her2− and have a recurrence score ≤ 25 as assessed by Oncotype Dx in the currently recruiting Tailor RT trial (NCT03488693).